Chemistry:PF-04457845
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Metabolism | CY3A4 |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C23H20F3N5O2 |
| Molar mass | 455.441 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
JZP150 (formerly PF-04457845) is an inhibitor of the enzyme fatty acid amide hydrolase (FAAH), with an IC50 of 7.2nM, and both analgesic and antiinflammatory effects in animal studies comparable to naproxen.[1]
JZP150 is currently being developed by Jazz Pharmaceuticals and is in a Phase 2 trial in the US for PTSD. Patients will be given 0.3mg orally once per day for up to 12 weeks, or 4.0mg orally once per day for up to 12 weeks, or a placebo.[2]
See also
- FAAH inhibitor
- 4-Nonylphenylboronic acid
- LY-2183240
- URB-597
- BIA 10-2474, problems in phase 1
References
- ↑ "Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor". ACS Medicinal Chemistry Letters 2 (2): 91–96. February 2011. doi:10.1021/ml100190t. PMID 21666860.
- ↑ "A Study of JZP150 in Adults With Posttraumatic Stress Disorder - Full Text View - ClinicalTrials.gov". https://clinicaltrials.gov/ct2/show/NCT05178316.
 |  |
